CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Clinical Trial

— CANPOS  

Official title:

CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02764606
• Other study ID #: D50832
• Status: Recruiting
• Start date: November 2013
• Est. completion date: December 2025

Study information

• Verified date: April 2019
• Source: Hospices Civils de Lyon
• Contact: Nicolas Girard
• Phone: +33427857700
• Email: nicolas.girard[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

CANPOS is a non-interventional study aiming at evaluate at the time of initial surgery the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer. This would represent a rational to develop personalized follow-up and prevention strategies

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• patients with a diagnosis or suspected for a diagnosis of lung cancer, non-small cell lung cancer

• age over 18 years

• patient naïve of any oncology treatment (excluding surgery alone) within the past 5 years

• patient who signed the informed consent by the study protocol

Exclusion criteria were:

• any ongoing treatment for cancer

• any history of cancer within 5 years before the diagnosis of lung cancer

• any psychological, sociological or geographical conditions that would not allow the study follow-up

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Biological:
• Serum and plasma samples
Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.

Locations

Country	Name	City	State
France	Hospices Civils de Lyon / Hôpital Neurologique Pierre Wertheimer	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Serum levels of osteoprotegerin	The serum levels of osteoprotegerin, as assessed by standard ELISA methods, will be measured to to evaluate at the time of initial surgery, the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer.	At the time of initial surgery